David Lebwohl - 01 Jan 2022 Form 4 Insider Report for Intellia Therapeutics, Inc. (NTLA)

Role: EVP, Chief Medical Officer
Signature: James Basta, attorney-in-fact
Issuer symbol: NTLA
Transactions as of: 01 Jan 2022
Net transactions value: -$117,964
Form type: 4
Filing time: 03 Mar 2022, 19:00:07 UTC
Previous filing: 09 Nov 2021
Next filing: 04 Mar 2022
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	NTLA	Common Stock	Options Exercise		+3,187	+36%		11,973	01 Jan 2022	Direct	F1, F2
transaction	NTLA	Common Stock	Sale	$117,964	-1,051	-8.8%	$112.24	10,922	01 Jan 2022	Direct	F3
transaction	NTLA	Common Stock	Award	$0	+13,816	+126%	$0.000000	24,738	01 Mar 2022	Direct	F4

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	NTLA	Restricted Stock Unit	Options Exercise	$0	-3,187	-25%	$0.000000	9,563	01 Jan 2022	Common Stock	3,187		Direct	F1, F5
transaction	NTLA	Stock Option (right to buy)	Award	$0	+13,816		$0.000000	13,816	01 Mar 2022	Common Stock	13,816	$79.85	Direct	F6

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Restricted stock units ("RSUs") convert into common stock on a one-for-one basis.
F2	Includes 72 shares acquired under the Intellia Therapeutics, Inc. 2016 Employee Stock Purchase Plan on December 31, 2021.
F3	Shares sold in sell-to-cover transaction in order to satisfy withholding taxes to be paid upon the vesting of RSUs on January 1, 2022.
F4	Based on a grant of restricted stock units representing a contingent right to receive one share of Intellia common stock for each restricted stock unit.
F5	On March 3, 2021, the reporting person was granted 12,750 RSUs pursuant to the Intellia Therapeutics, Inc. Amended and Restated 2015 Stock Option and Incentive Plan. Each RSU represents a contingent right to receive one share of the Company's common stock upon vesting, with 25% of the RSU vesting on January 1, 2022 and the remaining awards vesting as to 25% in substantially equal annual installments thereafter.
F6	This option was granted on March 1, 2022 with respect to shares of Common Stock, with 33% vesting on January 1, 2023 and the remaining 67% vesting in 24 substantially equal monthly installments thereafter.